Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole

Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype

(2012) M. Sugimoto et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy of Twice-Daily Rabeprazole for Reflux Esophagitis Patients Refractory to Standard Once-Daily Administration of PPI: The Japan-Based TWICE Study

(2012) Yoshikazu Kinoshita et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Dose–response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes

(2011) Seiichi Hayato et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population

(2008) Katsuyoshi Sugimoto et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism

(2008) Horng-Yuan Lou et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease

(2008) Naomi Uemura et al.   JOURNAL OF GASTROENTEROLOGY